Kelly E. McCann, MD, PhD, is an Assistant Professor of Medicine in the Division of Hematology/Oncology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). She earned her medical degree and her PhD in Cancer Biology studying DNA double-strand break repair by homologous recombination at Stanford University School of Medicine in California. She completed an internship and residency in Internal Medicine at Oregon Health & Science University in Portland and fellowships in Hematology and Oncology at UCLA. Dr. McCann is board-certified in Internal Medicine, Hematology, and Oncology.

Dr. McCann was a member of UCLA’s Translational Oncology Research Laboratories headed by Dr. Dennis Slamon, where she studied mechanisms of PARP inhibitors. Her laboratory research has been published in peer-reviewed journals, including Science, Bioinformatics, and Radiation Research. Her clinical interests are breast cancer, gynecologic oncology, and end of life care. She is a sub-investigator or principal investigator for numerous breast clinical trials at UCLA. She and Sara Hurvitz published a textbook through Elsevier on the biology and treatment of HER2+ breast cancer in August 2018.

She has a very strong interest in oncology education, leading to the development of a Solid Oncology curriculum for UCLA Internal Medicine residents and won Teacher of the Year in Hematology/Oncology in 2023. She is a member of the American Medical Association, the American College of Physicians, the American Society of Clinical Oncology, and the American Association for Cancer Research.